German-Dutch online pharmacy selling prescription and over-the-counter medicines and health products across Europe.
German-Dutch online pharmacy selling prescription and over-the-counter medicines and health products across Europe.
Sells medicines and health products shipped from central warehouses, with the non-prescription range carrying most revenue and prescriptions growing since Germany made electronic prescriptions mandatory in 2024. Germany is the largest market. The company is based in the Netherlands and was formerly named Shop Apotheke Europe.
In one line: A European Amazon Pharmacy/GoodRx hybrid.
Moat: narrow (scale, brand, regulatory licence). First-mover scale in German e-prescription market and pharmacy licences, but faces new entrants as e-Rx opens up.
Headquarters: Sevenum, Netherlands / Cologne, Germany · Founded: 2000 · Employees: 2,649
Size Redcare Pharmacy (RDC.DE) is a Germany Health Care company (Medical Distributors) with a market value of $1.50B, the 121st largest of 198 Germany companies the cockpit tracks. Shares closed at €66.50 on 18 Nov 2026.
Performance Over six months the shares gained 53.1%, against +1.4% for the median peer and -0.9% for the Germany market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 18.6% over the last twelve months (peer median +5.5%); the operating margin is 0.1% (peer median 3.2%).
Valuation It trades at 0.5× enterprise value to sales against a peer median of 0.5× (10th cheapest of 21).
Capital Return on invested capital runs 9.2 points below its cost of capital (9.6% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €3.34B | €2.94B | €2.37B | €1.80B | €1.20B |
| Revenue growth | — | +24% | +32% | +49% | — |
| Gross profit | €645M | €594M | €478M | €383M | €292M |
| EBITDA | €78.0M | €45.6M | €28.9M | €40.5M | -€15.3M |
| Net income | -€34.0M | -€37.7M | -€45.5M | -€12.0M | -€77.6M |
| Free cash flow | -€20.4M | -€56.3M | €11.4M | €51.8M | -€49.4M |
| Capital expenditure | €93.4M | €119M | €42.2M | €38.2M | €53.5M |
| Total debt | €354M | €416M | €278M | €275M | €241M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Redcare Pharmacy RDC.DE | $1.50B | +53% | +19% | 0% | 0.5× | n/a |
| Amazon AMZN | $2.90T | +1% | +15% | 13% | 3.9× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RDC.DE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.4% | +0.8% | lowest of 21 |
| 6-month return | +53.1% | +1.4% | 3rd highest of 21 |
| Distance from 52-week high | -16.8% | -17.8% | 10th highest of 21 |
| Revenue growth (TTM) | +18.6% | +5.5% | 2nd highest of 21 |
| Operating margin | 0.1% | 3.2% | 3rd lowest of 21 |
| EV / Sales | 0.5× | 0.5× | 10th cheapest of 21 |
| ROIC minus cost of capital | -9.2 pp | +1.7 pp | 2nd lowest of 21 |
| Net debt / EBITDA | 2.9× | 0.8× | most indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Redcare Pharmacy RDC.DE | Germany | $1.50B | +53% | +19% | 0% | 0.5× | n/a | n/a |
| Ship Healthcare 3360.T | Japan | $1.38B | +19% | +6% | 3% | 0.2× | -14.5% | +7.6% |
| Toho 8129.T | Japan | $1.64B | -5% | +4% | 1% | 0.1× | -4.6% | +5.1% |
| Shinva Medical Instrument 600587.SS | China | $1.10B | -10% | +6% | 5% | 0.6× | -6.9% | +1.2% |
| AS ONE 7476.T | Japan | $1.10B | +25% | +10% | 12% | 1.3× | 0.0% | +6.3% |
| DocMorris DOCM.SW | Switzerland | $1.08B | +169% | +11% | -8% | 1.0× | n/a | n/a |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.06B | -33% | +8% | 3% | 0.5× | -2.7% | +17.9% |
| Nanjing Pharmaceutical 600713.SS | China | $999M | -2% | +3% | 2% | 0.3× | n/a | n/a |
| Guangxi LiuYao 603368.SS | China | $975M | +1% | +2% | 5% | 0.4× | -9.7% | +6.0% |
| Arjo ARJO-B.ST | Sweden | $974M | +42% | 0% | 8% | 1.3× | -1.0% | +3.9% |
| Suzuken 9987.T | Japan | $2.36B | +8% | +5% | 1% | 0.1× | -10.4% | +3.2% |
| Entero Healthcare Solutions ENTERO.NS | India | $925M | +60% | +35% | 4% | 1.2× | 24.7% | +29.9% |
| Shanghai Haohai Biological Technology 6826.HK | Hong Kong | $897M | -24% | -5% | -2% | 1.9× | 17.0% | +12.4% |
| Hanmi Science 008930.KS | South Korea | $2.58B | +48% | +6% | 4% | 2.5× | 26.0% | +9.6% |
| Asker Healthcare ASKER.ST | Sweden | $2.69B | -14% | +12% | 7% | 1.8× | 4.7% | +12.7% |
| Alfresa 2784.T | Japan | $2.81B | -3% | +4% | 1% | 0.1× | -8.4% | +3.5% |
| Neuca NEU.WA | Poland | $795M | -9% | +8% | 2% | 0.3× | 5.3% | +8.1% |
| COSMOS Pharmaceutical 3349.T | Japan | $3.21B | +2% | +9% | 4% | 0.5× | n/a | n/a |
| Amplifon AMP.MI | Italy | $3.39B | +8% | 0% | 10% | 1.7× | 6.8% | +9.8% |
| MEDIPAL 7459.T | Japan | $3.70B | +15% | +4% | 1% | 0.1× | -7.2% | +3.5% |
| Arata 2733.T | Japan | $576M | -3% | +3% | 1% | 0.1× | -6.2% | +3.8% |